GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for slowing Alzheimer’s — a disease with few treatment options.

Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity--announced that Mr. Jesper Høiland has been ...

The stock of telemedicine provider Hims & Hers has been under intense pressure, shedding approximately 38% of its value since ...

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...

Marketers are positioning weight-loss shots as cosmetic elixirs for anyone who wants to lose a few pounds. Doctors warn that ...

Within the healthcare space, one company that combines fundamental safety with the high growth rates typically found in ...

A next-generation treatment from Novo Nordisk helped patients with diabetes lower their blood sugar and lose weight in a ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...